145 related articles for article (PubMed ID: 17180516)
1. Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
Uges JW; Vollaard AM; Wilms EB; Brouwer RE
Int J Clin Oncol; 2006 Dec; 11(6):467-70. PubMed ID: 17180516
[TBL] [Abstract][Full Text] [Related]
2. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
[TBL] [Abstract][Full Text] [Related]
3. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Bos AM; van der Graaf WT; Willemse PH
Acta Oncol; 2001; 40(4):541-2. PubMed ID: 11504316
[No Abstract] [Full Text] [Related]
4. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Jensen JN; Lock-Andersen J; Langer SW; Mejer J
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(3):174-5. PubMed ID: 12841619
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
7. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
Tyson AM; Gay WE
Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
10. Recall phenomenon following epirubicin.
Wilson J; Carder P; Gooi J; Nishikawa H
Clin Oncol (R Coll Radiol); 1999; 11(6):424-5. PubMed ID: 10663338
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
[TBL] [Abstract][Full Text] [Related]
12. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
13. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
[TBL] [Abstract][Full Text] [Related]
14. [Locoregional chemotherapy of locally advanced breast cancer in a pre-treated patient: case report].
Vagliasindi A; Valmori L; Bertagni A; Campisi A; Milandri C; Gianpalma E; Calzolai F; Golfieri DR; Verdecchia GM
Tumori; 2003; 89(4 Suppl):152-4. PubMed ID: 12903577
[TBL] [Abstract][Full Text] [Related]
15. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy for breast cancer--30 years later.
Levine MN; Whelan T
N Engl J Med; 2006 Nov; 355(18):1920-2. PubMed ID: 17079767
[No Abstract] [Full Text] [Related]
18. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
19. [Primary systemic therapy in breast cancer patients (2007-2010)].
Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
[TBL] [Abstract][Full Text] [Related]
20. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
